Table 13.30Incremental cost effectiveness results including a strategy of treating all babies with only one risk factor

Test strategyCostQALYsIncremental costIncremental QALYsICER
Test only if symptoms and signs develop£12,846,7266896---
Test all babies with a risk factor within 8 hours£12,442,8167159−£403,910263.1Dominant
Treat all babies with a risk factor£16,596,6307188£4,153,81529.2£142,088

ICER incremental cost effectiveness ratio, QALY quality adjusted life year

Dominant = more effective and less expensive than the comparator

From: 13, Health economics

Cover of Antibiotics for Early-Onset Neonatal Infection
Antibiotics for Early-Onset Neonatal Infection: Antibiotics for the Prevention and Treatment of Early-Onset Neonatal Infection.
NICE Clinical Guidelines, No. 149.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2012 Aug.
Copyright © 2012, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.